EpiEndo Pharmaceuticals is a clinical biopharmaceutical company focused on novel solutions for chronic airway diseases.
EpiEndo Pharmaceuticals has raised $23.4M in total funding. The most recent round was Series A. The last funding was announced in August 2021.
EpiEndo Pharmaceuticals's investors include European Innovation Council, Brunnur Ventures, EISMEA, Flerie Invest, Kvika Asset Management.
EpiEndo Pharmaceuticals is headquartered in Reykjavík, Iceland.
EpiEndo Pharmaceuticals is a clinical biopharmaceutical company focused on novel solutions for chronic airway diseases.
EpiEndo Pharmaceuticals is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"EpiEndo Pharmaceuticals — Funding & Investors." VCBacked, August 18, 2021, https://www.vcbacked.co/company/epiendo-pharmaceuticals. Accessed August 22, 2026.
VCBacked. (2021). EpiEndo Pharmaceuticals — Funding & Investors. Retrieved August 22, 2026, from https://www.vcbacked.co/company/epiendo-pharmaceuticals
{{cite web |title=EpiEndo Pharmaceuticals — Funding & Investors |url=https://www.vcbacked.co/company/epiendo-pharmaceuticals |website=VCBacked |access-date=August 22, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated